Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 3/2016

01.09.2016 | short review

Acute myeloid leukemia: highlights from ASH 2015

verfasst von: MD, MBA Prof. Michael Pfeilstöcker

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Despite of the progress achieved in recent years for acute myeloid leukemia (AML) treatment, there is still a need for improvement, both for younger and elderly patients. This review covers studies for AML presented at the ASH 2015 annual meeting. The presentations selected offer a glimpse of the future of AML treatment. Also in AML insights into the molecular pathogenesis can be translated into clinical practice where a major step has been set with the first positive trial with respect to overall survival for the tyrosine kinase inhibitor midostaurin. Also for older patients, unfit for chemotherapy, therapy options are increasingly available. Individualized therapies will require both new trial designs and new approaches for patient assessment and clinical decision making.
Literatur
1.
Zurück zum Zitat Papaemmanuil E, Gerstung M, Bullinger L, et al. Dissecting genetic and phenotypic heterogeneity to map molecular phylogenies and deliver personalized outcome and treatment predictions in AML. Blood. 2015;126:803. Papaemmanuil E, Gerstung M, Bullinger L, et al. Dissecting genetic and phenotypic heterogeneity to map molecular phylogenies and deliver personalized outcome and treatment predictions in AML. Blood. 2015;126:803.
2.
Zurück zum Zitat Stone RM, Mandrekar S, Sanford BL, et al. The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18–60 with FLT3 mutations (muts): an international prospective randomized (rand) P‑controlled bouble-blind trial (CALGB 10603/RATIFY [Alliance]). Blood. 2015;126:6. CrossRef Stone RM, Mandrekar S, Sanford BL, et al. The multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18–60 with FLT3 mutations (muts): an international prospective randomized (rand) P‑controlled bouble-blind trial (CALGB 10603/RATIFY [Alliance]). Blood. 2015;126:6. CrossRef
3.
Zurück zum Zitat Schlenk R, Döhner K, Salih H, et al. Midostaurin in combination with intensive induction and as single agent maintenance therapy after consolidation therapy with allogeneic hematopoietic stem cell transplantation or high-dose Cytarabine (NCT01477606). Blood. 2015;126:322. Schlenk R, Döhner K, Salih H, et al. Midostaurin in combination with intensive induction and as single agent maintenance therapy after consolidation therapy with allogeneic hematopoietic stem cell transplantation or high-dose Cytarabine (NCT01477606). Blood. 2015;126:322.
4.
Zurück zum Zitat Uy GL, Mandrekar S, Laumann K, et al. Addition of sorafenib to chemotherapy improves the overall survival of older adults with FLT3-ITD mutated acute myeloid leukemia (AML) (Alliance C11001). Blood. 2015;126:319. CrossRef Uy GL, Mandrekar S, Laumann K, et al. Addition of sorafenib to chemotherapy improves the overall survival of older adults with FLT3-ITD mutated acute myeloid leukemia (AML) (Alliance C11001). Blood. 2015;126:319. CrossRef
5.
Zurück zum Zitat Stein EM, DiNardo C, Altman JK, et al. Safety and efficacy of AG-221, a potent inhibitor of mutant IDH2 that promotes differentiation of myeloid cells in patients with advanced hematologic malignancies: results of a phase 1/2 trial. Blood. 2015;126:323. Stein EM, DiNardo C, Altman JK, et al. Safety and efficacy of AG-221, a potent inhibitor of mutant IDH2 that promotes differentiation of myeloid cells in patients with advanced hematologic malignancies: results of a phase 1/2 trial. Blood. 2015;126:323.
6.
Zurück zum Zitat Foran JM, Sun Z, Claxton DF, et al. North American leukemia, intergroup phase III randomized trial of single agent clofarabine as induction and post-remission therapy, and Decitabine as maintenance therapy in newly-diagnosed acute myeloid leukemia in older adults (age ≥60 years): a trial of the ECOG-ACRIN cancer research group (E2906). Blood. 2015;126:217. Foran JM, Sun Z, Claxton DF, et al. North American leukemia, intergroup phase III randomized trial of single agent clofarabine as induction and post-remission therapy, and Decitabine as maintenance therapy in newly-diagnosed acute myeloid leukemia in older adults (age ≥60 years): a trial of the ECOG-ACRIN cancer research group (E2906). Blood. 2015;126:217.
7.
Zurück zum Zitat Thomas X, De Botton S, Chevret S, et al. Clofarabine-based consolidation improves relapse-free survival of younger adults with non-favorable acute myeloid leukemia (AML) in first remission: results of the randomized ALFA-0702/Clara study (NCT 00932412). Blood. 2015;126:218. Thomas X, De Botton S, Chevret S, et al. Clofarabine-based consolidation improves relapse-free survival of younger adults with non-favorable acute myeloid leukemia (AML) in first remission: results of the randomized ALFA-0702/Clara study (NCT 00932412). Blood. 2015;126:218.
8.
Zurück zum Zitat Russell NH, Hills RK, Freeman S, et al. A comparison of 1 or 2 courses of high dose cytarabine as consolidation in younger patients with AML: first results of the UK NCRI AML17 trial. Blood. 2015;126:221. Russell NH, Hills RK, Freeman S, et al. A comparison of 1 or 2 courses of high dose cytarabine as consolidation in younger patients with AML: first results of the UK NCRI AML17 trial. Blood. 2015;126:221.
9.
Zurück zum Zitat Röllig C, Kramer M, Gabrecht M, et al. Randomized comparison of intermediate-dose cytarabine plus mitoxantrone (IMA) versus standard-dose cytarabine plus daunorubicin (DA) for induction therapy in AML patients 〉60 years. results from the SAL 60+ trial. Blood. 2015;126:222. CrossRef Röllig C, Kramer M, Gabrecht M, et al. Randomized comparison of intermediate-dose cytarabine plus mitoxantrone (IMA) versus standard-dose cytarabine plus daunorubicin (DA) for induction therapy in AML patients 〉60 years. results from the SAL 60+ trial. Blood. 2015;126:222. CrossRef
10.
Zurück zum Zitat Ades L, Thomas X, Guerci-Bresler A, et al. Is arsenic trioxide (ATO) required in the treatment of standard risk newly diagnosed APL? Analysis of a randomized trial (APL 2006) by the french belgian swiss APL group. Blood. 2015;126:451. Ades L, Thomas X, Guerci-Bresler A, et al. Is arsenic trioxide (ATO) required in the treatment of standard risk newly diagnosed APL? Analysis of a randomized trial (APL 2006) by the french belgian swiss APL group. Blood. 2015;126:451.
11.
Zurück zum Zitat Pleyer L, Burgstaller S, Stauder R, et al. Azacitidine in acute myeloid leukemia with 〉30 % bone marrow blasts and 〈15 G/L white blood cell count: results from the Austrian Azacitidine Registry of the AGMT Study Group versus randomized controlled phase III clinical trial data. Blood. 2015;126:2515. Pleyer L, Burgstaller S, Stauder R, et al. Azacitidine in acute myeloid leukemia with 〉30 % bone marrow blasts and 〈15 G/L white blood cell count: results from the Austrian Azacitidine Registry of the AGMT Study Group versus randomized controlled phase III clinical trial data. Blood. 2015;126:2515.
12.
Zurück zum Zitat Seymour JF, Silverman LR, Döhner H, et al. The safety and tolerability of azacitidine (AZA) are comparable in patients with acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes (MDS). Blood. 2015;126:3754. Seymour JF, Silverman LR, Döhner H, et al. The safety and tolerability of azacitidine (AZA) are comparable in patients with acute myeloid leukemia (AML) or higher-risk myelodysplastic syndromes (MDS). Blood. 2015;126:3754.
13.
Zurück zum Zitat DiNardo C, Pollyea D, Pratz K, et al. A phase 1b study of venetoclax (ABT-199/GDC-0199) in combination with decitabine or azacitidine in treatment-naive patients with acute myelogenous leukemia who are ≥ to 65 years and not eligible for standard induction therapy. Blood. 2015;126:327. CrossRef DiNardo C, Pollyea D, Pratz K, et al. A phase 1b study of venetoclax (ABT-199/GDC-0199) in combination with decitabine or azacitidine in treatment-naive patients with acute myelogenous leukemia who are ≥ to 65 years and not eligible for standard induction therapy. Blood. 2015;126:327. CrossRef
14.
Zurück zum Zitat Garcia-Manero G, Berdeja JD, Komrokji RS, et al. A randomized, placebo-controlled, phase II study of pracinostat in combination with azacitidine (AZA) in patients with previously untreated myelodysplastic syndrome (MDS). Blood. 2015;126:911. Garcia-Manero G, Berdeja JD, Komrokji RS, et al. A randomized, placebo-controlled, phase II study of pracinostat in combination with azacitidine (AZA) in patients with previously untreated myelodysplastic syndrome (MDS). Blood. 2015;126:911.
15.
Zurück zum Zitat Fathi AT, Erba HP, Lancet JE, et al. SGN-CD33A plus hypomethylating agents: a novel, well-tolerated regimen with high remission rate in frontline unfit AML. Blood. 2015;126:454. CrossRef Fathi AT, Erba HP, Lancet JE, et al. SGN-CD33A plus hypomethylating agents: a novel, well-tolerated regimen with high remission rate in frontline unfit AML. Blood. 2015;126:454. CrossRef
16.
Zurück zum Zitat Daver N, Kantarjian HM, Garcia-Manero G, et al. Phase I/II study of vosaroxin and decitabine in newly diagnosed older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). Blood. 2015;126:461. Daver N, Kantarjian HM, Garcia-Manero G, et al. Phase I/II study of vosaroxin and decitabine in newly diagnosed older patients (pts) with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). Blood. 2015;126:461.
17.
Zurück zum Zitat Kantarjian HM, Roboz GJ, Kropf PL, et al. Comparison of efficacy and safety results in 103 treatment-naïve acute myeloid leukemia (TN-AML) patients not candidates for intensive chemotherapy using 5‑day and 10-day regimens of guadecitabine (SGI-110), a novel hypomethylating agent (HMA). Blood. 2015;126:458. Kantarjian HM, Roboz GJ, Kropf PL, et al. Comparison of efficacy and safety results in 103 treatment-naïve acute myeloid leukemia (TN-AML) patients not candidates for intensive chemotherapy using 5‑day and 10-day regimens of guadecitabine (SGI-110), a novel hypomethylating agent (HMA). Blood. 2015;126:458.
18.
Zurück zum Zitat Voso MT, Leone G, Piciocchi A, et al. Feasibililty of azacitidine as bridge to allogeneic stem cell transplantation in patients with higher-risk MDS or low-blast count AML: results of the BMT-AZA multicenter prospective study. Blood. 2015;126:66. Voso MT, Leone G, Piciocchi A, et al. Feasibililty of azacitidine as bridge to allogeneic stem cell transplantation in patients with higher-risk MDS or low-blast count AML: results of the BMT-AZA multicenter prospective study. Blood. 2015;126:66.
19.
Zurück zum Zitat Scott BL, Pasquini MC, Logan B, et al. Results of a phase III randomized, multi-center study of allogeneic stem cell transplantation after high versus reduced intensity conditioning in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): blood and marrow transplant clinical trials network (BMT CTN) 0901. Blood. 2015;126:LBA-8. Scott BL, Pasquini MC, Logan B, et al. Results of a phase III randomized, multi-center study of allogeneic stem cell transplantation after high versus reduced intensity conditioning in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): blood and marrow transplant clinical trials network (BMT CTN) 0901. Blood. 2015;126:LBA-8.
20.
Zurück zum Zitat Ferguson P, Hills RK, Grech A, et al. An operational definition of primary refractory acute myeloid leukaemia which allows early identification of patients for whom allogeneic stem cell transplantation represents the only curative therapy. Blood. 2015;126:559. CrossRef Ferguson P, Hills RK, Grech A, et al. An operational definition of primary refractory acute myeloid leukaemia which allows early identification of patients for whom allogeneic stem cell transplantation represents the only curative therapy. Blood. 2015;126:559. CrossRef
21.
Zurück zum Zitat Lee SC, Dvinge H, Kim E, et al. Therapeutic targeting of spliceosomal mutant myeloid leukemias through modulation of splicing catalysis. Blood. 2015;126:4. CrossRef Lee SC, Dvinge H, Kim E, et al. Therapeutic targeting of spliceosomal mutant myeloid leukemias through modulation of splicing catalysis. Blood. 2015;126:4. CrossRef
Metadaten
Titel
Acute myeloid leukemia: highlights from ASH 2015
verfasst von
MD, MBA Prof. Michael Pfeilstöcker
Publikationsdatum
01.09.2016
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2016
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-016-0275-3